Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.40

0.0%

Nov 28 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (857)	3/13/2001 3:40:46 PM
From: Mark Bong	Read Replies (1) of 1475

Nigel, I doubt that MEDI is playing that game, but the thought did cross my mind. More importantly, I heard BTRN management say that one of the primary purposes of the ELIGIX transaction was to obtain near term cash flow from product sales to fund R & D and operational cash flow needs. So now they say that they need funds for operations and are exploring options...I agree with Richard that MEDI slow poking has hurt the timing of profits for BTRN, but BTRN management has to get its act together and focus on product sales of Eligix and not more dilution of ownership. I had hoped that Eligix sales would put a nice floor under the stock price so new funds could be raised without much dilution. Just my 2cents or shillings worth or whatever. Lets monitor this one closely.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next